A staggering 80% of clinical trials are delayed or shut down due to enrollment challenges, with half of those delays occurring at the site level. Two-thirds of principal investigators leave research after conducting a single trial. It’s time for a change.
Watch Paul Evans, Nick Campbell, Nick Spittal, and Craig Koch discuss Velocity’s unique model, the purpose behind its growth, and the significant efficiencies being unlocked for clinical trials worldwide. Velocity is leading the transformation by:
- Utilizing global reach to deliver the right sites and patients.
- Leveraging extensive data to enhance performance and predictability.
- Empowering sites with centralized support to ensure quality and efficiency.
- Developing proprietary, AI-enabled technologies for sites and patients.
